Sartorius Stedim Biotech Acquires UK-Based CRO, BioOutsource
Sartorius Stedim Biotech (SSB) acquired the Scottish company BioOutsource. The privately owned company based in Glasgow, UK, has been operating in the biotechnology market since 2007, and in the last twelve months earned revenue of around 9 million euros with approx. 85 employees. The contractual parties agreed not to disclose any further details of the transaction.
BioOutsource provides contract testing services to global biopharmaceutical clients in order to monitor the safety and quality of biologic drugs and vaccines. In particular, the company specializes in offering a comprehensive suite of services for the fast growing biosimilar industry. Its assays are used in the early phases of drug characterization and comparability and for lot release testing of novel therapeutics.
This acquisition will develop SSB's service offering throughout the drug development pathway.